BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23220853)

  • 21. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular cloning, in vitro expression and bioactivity of rabbit transforming growth factor-beta receptor type II (rTGF-βRII).
    Liu H; Wang X; Wang C; Yuan X; Bao H; Fu X; Chu Y
    Vet Immunol Immunopathol; 2011 Mar; 140(1-2):55-62. PubMed ID: 21167609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal nucleotide repeat sequence in the TGF-betaRII gene in hepatocellular carcinoma and in uninvolved liver tissue.
    Enomoto A; Esumi M; Yamashita K; Takagi K; Takano S; Iwai S
    J Pathol; 2001 Oct; 195(3):349-54. PubMed ID: 11673833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short hairpin RNA modulates transforming growth factor beta signaling in life-threatening liver failure in mice.
    Mizuguchi Y; Yokomuro S; Mishima T; Arima Y; Shimizu T; Kawahigashi Y; Kanda T; Yoshida H; Takizawa T; Tajiri T
    Gastroenterology; 2005 Nov; 129(5):1654-62. PubMed ID: 16285963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
    Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA
    Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization.
    Boldrini L; Calcinai A; Samaritani E; Pistolesi F; Mussi A; Lucchi M; Angeletti CA; Basolo F; Fontanini G
    Br J Cancer; 2000 Aug; 83(4):480-6. PubMed ID: 10945495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis.
    Kubo M; Ihn H; Yamane K; Tamaki K
    J Rheumatol; 2002 Dec; 29(12):2558-64. PubMed ID: 12465152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.
    Kaklamani VG; Baddi L; Liu J; Rosman D; Phukan S; Bradley C; Hegarty C; McDaniel B; Rademaker A; Oddoux C; Ostrer H; Michel LS; Huang H; Chen Y; Ahsan H; Offit K; Pasche B
    Cancer Res; 2005 Apr; 65(8):3454-61. PubMed ID: 15833881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 alterations are not associated with microsatellite instability or p53 mutations in invasive urothelial carcinoma of the urinary bladder.
    Saetta AA; Korkolopoulou P; Karlou M; Levidou G; Goudopoulou A; Thymara I; Stamatelli A; Tzivras M; Michalopoulos NV; Thomas-Tsagli E; Patsouris E
    Pathology; 2007 Aug; 39(4):425-32. PubMed ID: 17676485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Localization of recognition site between transforming growth factor-beta1 (TGF-beta1) and TGF beta receptor type II: possible implications in breast cancer.
    Ivanović V; Demajo M; Todorović-Raković N; Nikolić-Vukosavljević D; Nesković-Konstantinović Z; Krtolica K; Veljković V; Prljić J; Dimitrijević B
    Med Hypotheses; 2004; 62(5):727-32. PubMed ID: 15082097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.
    Lücke CD; Philpott A; Metcalfe JC; Thompson AM; Hughes-Davies L; Kemp PR; Hesketh R
    Cancer Res; 2001 Jan; 61(2):482-5. PubMed ID: 11212236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.
    Petrarca CR; Brunetto AT; Duval V; Brondani A; Carvalho GP; Garicochea B
    Clin Breast Cancer; 2011 Apr; 11(2):129-34. PubMed ID: 21569999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
    Uhlman DL; Nguyen P; Manivel JC; Zhang G; Hagen K; Fraley E; Aeppli D; Niehans GA
    Clin Cancer Res; 1995 Aug; 1(8):913-20. PubMed ID: 9816062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-beta type II receptor in a short-term in vitro assay.
    Fortunel N; Hatzfeld J; Kisselev S; Monier MN; Ducos K; Cardoso A; Batard P; Hatzfeld A
    Stem Cells; 2000; 18(2):102-11. PubMed ID: 10742382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis.
    Sin S; Bonin F; Petit V; Meseure D; Lallemand F; Bièche I; Bellahcène A; Castronovo V; de Wever O; Gespach C; Lidereau R; Driouch K
    J Natl Cancer Inst; 2011 Sep; 103(17):1323-37. PubMed ID: 21832234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
    Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
    Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Transforming growth factor beta receptor II mutations in RER positive colorectal cancers].
    Lai MD; Huang ZD; Huang Q; Chen J
    Zhonghua Bing Li Xue Za Zhi; 2004 Feb; 33(1):6-10. PubMed ID: 14989920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.